Business news

MINSK, 2 August (BelTA) – An R&D center named after Yusuf Hamied will be created at premises of the state enterprise Academpharm of the National Academy of Sciences of Belarus (NASB), the NASB press service told BelTA.

The R&D center is expected to manufacture medications using a complete cycle – from a scientific idea to manufacturing. It will be built with Indian assistance.

The ceremony to open a landscape complex in honor of the project will take place on 6 August. A delegation of the Indian pharmaceutical company Cipla Limited led by the company’s Non-Executive Chairman Yusuf Khwaja Hamied will take part in the ceremony. Yusuf Hamied is an honorary member of the National Academy of Sciences of Belarus.

The Cipla Limited delegation will stay in Belarus on 5-8 August. The purpose of the visit is to discuss promising ways of expanding cooperation between the National Academy of Sciences of Belarus and Indian organizations, present promising cooperation avenues, and discuss the concept of the pharmaceutical R&D center.

Yusuf Khwaja Hamied is a leading Indian scientist. He is known internationally primarily for his desire to provide medications to fight AIDS and other grave diseases to patients in the world’s poorest countries.

Founded in 1935, Cipla Limited is focused on development, chemical synthesis, and production of over 1,500 ready-made medications. It offers antitumor medications, bronchodilators, corticosteroids, immunosuppressants, chemotherapeutic and antiretroviral agents, antibiotics, and antidepressants. Cipla Limited is present in 150 countries across the globe.